Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Avelumab in Unresectable/Metastatic, Progressive Grade 2-3 Neuroendocrine Tumors

NCT03278379 is registered in ClinicalTrials.gov with Sunnybrook Health Sciences Centre as lead sponsor.

NCT NCT03278379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03278379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Avelumab in Unresectable/Metastatic, Progressive Grade 2-3 Neuroendocrine Tumors
Lead sponsor
Sunnybrook Health Sciences Centre
Phase
Phase 2
Overall status
Completed
Start date
November 15, 2017
Completion date
July 6, 2023
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumors